Hopp til hovedinnhold


Sist revidert:
Sist revidert av:

  1. Folkehelseinstituttet. Vaksinasjonsveilederen. HPV-vaksine (Humant papillomavirus) - veileder for helsepersonell. Sist oppdatert 30.09.2022. Siden lest 28.06.2023
  2. Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD009069. DOI: 10.1002/14651858.CD009069.pub3. The Cochrane Library  
  3. Goss MA, Lievano F, Seminack MM, Dana A. No adverse signals observed after exposure to human papillomavirus type 6/11/16/18 vaccine during pregnancy: 6-year pregnancy registry data. Obstet Gynecol 2014. doi:10.1097/01.AOG.0000447430.00051.ba DOI  
  4. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114: 1179-88. PubMed  
  5. Feiring B, Laake I, Christiansen IK, et al. Substantial decline in prevalence of vaccine-type and non-vaccine type HPV in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway. Journal of Infectious Diseases 2018. doi: 10.1093/infdis/jiy432 DOI  
  6. Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016. doi: 10.1542/peds.2015-1968 DOI  
  7. Sæterdal I, Couto E, Juvet L, Harboe I, Klemp M. Effect of catch-up HPV vaccination of young women. Report from Kunnskapssenteret no. 4−2014. Oslo: Norwegian Knowledge Centre for the Health Services, 2014.
  8. Garland SM. The Australian Experience With the Human. Clinical Therapeutics 2014; 36: 17-23. doi:10.1016/j.clinthera.2013.12.005 DOI  
  9. Kuh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet 2017. pmid:28886907 PubMed  
  10. Fairley CK, Hockin JS, Gurrin LC, et al. Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women. Sex Transm Infect 2009; : PMID: 19837728. PubMed  
  11. Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros‐Balta AX, Low N, Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No.: CD013479. DOI: 10.1002/14651858.CD013479 DOI  
  12. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?. Gynecologic Oncology 2013; 130: 264-68. pmid: 23623831 PubMed  
  13. Dion GR, Teng S, Boyd LR, et al. Adjuvant Human Papillomavirus Vaccination for Secondary Prevention: A Systematic Review. JAMA Otolaryngol Head Neck Surg 2017; 143: 614-22. pmid:28334393 PubMed  
  14. Nasman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-6. PubMed  
  15. Statens legemiddelverk. Bivirkningsmelding for HPV-vaksinen, oppdaterte tall per 31. juli 2018. SLV 2018.
  16. Feiring B, Laake I, Bakken IJ et al. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway. Vaccina 2017; 35: 4203-12. pmid:28648542 PubMed  
  17. Scheller NM, Svanstrom H, Pasternak B, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015 Jan 6;313(1):54-61. doi: 10.1001/jama.2014.16946. (Original) PMID: 25562266 PubMed  
  18. Ingen sammenheng mellom HPV-vaksine og POTS og CRPS. Statens legemiddelverk, 5.november 2015
  19. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM): Vaccins anti-HPV et risque de maladies autoimmunes: étude pharmacoépidémiologique. 14.09.2015
  20. Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine 2017;35(13):1729-32 PubMed  
  21. Liu EY, Smith LM, Ellis AK, et al. Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study. CMAJ. 2018; 190:E648-E655. PMID: 29807937 PubMed  
  22. Dillner J. The FUTURE I/II Study Group. For year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493. BMJ (DOI)  
  23. Hviid A, Thorsen NM, Valentiner-Branth P, et al. Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: Population based, self-controlled, case series analysis. BMJ 2020; 370: m2930. pmid:32878745 PubMed  
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL